Increased understanding of the immunopathology of inflammatory bowel disease (IBD) has
led to the development of targeted therapies and has unlocked a new era in IBD treatment …

Inflammatory Bowel Diseases had their first peak in incidence in countries in North America,
Europe, and Oceania and are currently experiencing a new acceleration in incidence …

New targets in inflammatory bowel disease therapy: 2021 : Current Opinion in
Gastroenterology New targets in inflammatory bowel disease therapy: 2021 : Current …

Background The landscape of inflammatory bowel disease (IBD) treatment is rapidly
expanding with the development of new therapeutic options. Aim To review the mechanisms …

Inflammatory bowel disease (IBD) still presents major challenges to the understanding of its
cause, mechanisms of inflammation, and therapeutic choices to control the damaged tissue …

Inflammatory bowel diseases (IBDs) may result from dysregulated mucosal immune
responses directed toward the resident intestinal microbiota. This review describes the …

Inflammatory bowel disease (IBD) is an immune-mediated inflammatory condition causing
inflammation of gastrointestinal and systemic cells, with an increasing prevalence …

Inflammatory bowel disease (IBD) is a systemic disease associated with a large number of
extraintestinal manifestations (EIM). EIM are present in 15–20% of patients with ulcerative …

Biological agents for inflammatory bowel diseases (IBD) targeting tumor necrosis factor
(TNF) have changed the way to treat IBD refractory to standard medications and allowed us …

Background: Inflammatory bowel diseases patients eligible for biological therapy represent
a group with considerable disease burden and biologics only achieve 40% clinical …